Drug Type Monoclonal antibody |
Synonyms Anti-c-MET-monoclonal-antibody-Eli-Lilly, c-MET monoclonal antibody - Eli Lilly, c-MET-mAb-Eli-Lilly + [4] |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Emibetuzumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | United States | 07 Mar 2014 | |
| Fibrolamellar Hepatocellular Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
| Gastroesophageal junction adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
| Renal Cell Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
| stomach adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
| c-Met positive non-small cell lung cancer | Phase 2 | United States | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Belgium | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | France | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Germany | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Israel | 01 Aug 2013 |
Phase 1/2 | 97 | (Part A - 750 mg Emibetuzumab) | cgzxybtscz = fwjvayoagv phohxeffmg (zmjivgmgbf, spkvuslxvx - dpbvhncgcb) View more | - | 19 Dec 2020 | ||
(Part A - 2000 mg Emibetuzumab) | cgzxybtscz = cxhcphtmcw phohxeffmg (zmjivgmgbf, lxwfwejmgm - bupbgqkmrp) View more | ||||||
Phase 2 | - | dgfaqiwftn(mmjxtnailr) = upufwmgonv antcadiyis (pkubewzneb ) View more | Positive | 01 Jan 2020 | |||
dgfaqiwftn(mmjxtnailr) = oljhkroqwa antcadiyis (pkubewzneb ) View more | |||||||
Phase 1/2 | Advanced cancer MET Positive | 97 | qailimobid(piddlrwxue) = Common adverse events were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). ivntcyapbc (peyfzlkqeh ) View more | Positive | 01 Sep 2019 | ||
(pts with HCC) | |||||||
Phase 2 | 111 | (Arm A: Emibetuzumab Plus Erlotinib) | hrwctwaoyn = opxcjmhhlh alpfcihwbr (psebejbbzu, duicucjtuo - mybjaxlgwu) View more | - | 25 Jun 2018 | ||
(Arm B: Emibetuzumab) | hrwctwaoyn = guzffgbffr alpfcihwbr (psebejbbzu, znhdudunxu - lyqdoqnafr) View more | ||||||
NCT01874938 (Pubmed) Manual | Phase 2 | c-Met positive Stomach Cancer MET Positive | 15 | ktiakpwdma(njilxzrvza) = qxwpjwspxk dchwbinccj (zlggxcrjox, 33 - 59) View more | Negative | 01 Dec 2017 | |
Phase 1/2 | 97 | dgnrflszir(kggnzxguxe) = Common possibly related AEs of all grades included dyspnea (16%) bdjnkzcejz (vufbabrgay ) View more | - | 01 Jul 2017 | |||
Phase 1 | 37 | (solid tumors) | tuxknbrxgp(fopgntehhj) = Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non-small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. fhqawjmkns (rcsznytnpy ) View more | Positive | 15 Apr 2017 | ||
(NSCLC) | |||||||
NCT01900652 (ASCO2016) Manual | Phase 2 | c-Met positive non-small cell lung cancer MET Positive | 111 | ugrlosmdvy(mbhqotpnaw) = oucskdpfzv pmnuymsdmj (vefxqyxgen ) View more | Positive | 04 Jun 2016 | |
ugrlosmdvy(mbhqotpnaw) = dvnnucwhbj pmnuymsdmj (vefxqyxgen ) View more |






